Taisho Targets End-2008 Start for SGLT2 Inhibitor Phase III Tests

摘要

Taisho Pharmaceutical plans to begin as early as the end of 2008 phase III clinical trials in Japan on its sodium glucose co-transporter 2 inhibitor,coded TS-033,as a diabetes treatment drug.SGLT2 inhibitors are a new class of diabetes therapy with a different mechanism from diabetes drugs in use today,which are based on improving insulin resistance and promoting its secretion.